UA82564C2 - Антиретровирусная фармацевтическая композиция замедленного высвобождения и способ ее изготовления - Google Patents
Антиретровирусная фармацевтическая композиция замедленного высвобождения и способ ее изготовления Download PDFInfo
- Publication number
- UA82564C2 UA82564C2 UAA200604821A UAA200604821A UA82564C2 UA 82564 C2 UA82564 C2 UA 82564C2 UA A200604821 A UAA200604821 A UA A200604821A UA A200604821 A UAA200604821 A UA A200604821A UA 82564 C2 UA82564 C2 UA 82564C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutically acceptable
- composition
- composition according
- controlled release
- zidovudine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 238000013270 controlled release Methods 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000009472 formulation Methods 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims abstract description 62
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 40
- 229960002555 zidovudine Drugs 0.000 claims abstract description 34
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 34
- 229960000689 nevirapine Drugs 0.000 claims abstract description 31
- 229960001627 lamivudine Drugs 0.000 claims abstract description 28
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 27
- 230000000798 anti-retroviral effect Effects 0.000 claims abstract description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 208000030507 AIDS Diseases 0.000 claims abstract description 11
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 8
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims abstract description 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims abstract description 4
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 21
- 229960003804 efavirenz Drugs 0.000 claims description 21
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 21
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 239000003085 diluting agent Substances 0.000 claims description 18
- 159000000007 calcium salts Chemical class 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 claims description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 229920003086 cellulose ether Polymers 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 150000007513 acids Chemical class 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 230000001050 lubricating effect Effects 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229920003124 powdered cellulose Polymers 0.000 claims description 8
- 235000019814 powdered cellulose Nutrition 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000003879 lubricant additive Substances 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000000648 calcium alginate Substances 0.000 claims description 4
- 229960002681 calcium alginate Drugs 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000010407 ammonium alginate Nutrition 0.000 claims description 2
- 239000000728 ammonium alginate Substances 0.000 claims description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000001055 magnesium Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 9
- 239000006187 pill Substances 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 description 10
- 235000019691 monocalcium phosphate Nutrition 0.000 description 8
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical group [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940124522 antiretrovirals Drugs 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 229960004748 abacavir Drugs 0.000 description 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 3
- 239000003903 antiretrovirus agent Substances 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 102100023876 Rhombotin-2 Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- NZTHDEBIUKWGSX-UHFFFAOYSA-K [Na+].[Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O Chemical compound [Na+].[Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O NZTHDEBIUKWGSX-UHFFFAOYSA-K 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical group [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229940080431 lamivudine 150 mg Drugs 0.000 description 1
- 229940029101 lamivudine 300 mg Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229940079500 nevirapine 200 mg Drugs 0.000 description 1
- 229940073135 nevirapine 400 mg Drugs 0.000 description 1
- 239000002667 nucleating agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к антиретровирусной фармацевтической композиции из трех лекарственных препаратов, обеспечивающей сочетание замедленного и немедленного высвобождения действующих ингредиентов. Композиция обеспечивает поступление требуемых доз действующих ингредиентов ламивудина, зидовудина или их фармацевтически приемлемых производных, а также немедленное высвобождение как минимум одного избирательного ингибитора обратной транскриптазы ненуклеозидной природы (NNRTI), предпочтительно невирапина или его фармацевтически приемлемого производного с фармацевтически приемлемыми вспомогательными ингредиентами. Композиция требует однократного суточного приема, что способствует соблюде
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN417MU2003 | 2003-10-01 | ||
| PCT/IN2004/000306 WO2005048978A2 (en) | 2003-10-01 | 2004-09-29 | A controlled release pharmaceutical composition and a process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82564C2 true UA82564C2 (ru) | 2008-04-25 |
Family
ID=34611194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200604821A UA82564C2 (ru) | 2003-10-01 | 2004-09-29 | Антиретровирусная фармацевтическая композиция замедленного высвобождения и способ ее изготовления |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070231385A1 (ru) |
| EP (1) | EP1673072B1 (ru) |
| CN (1) | CN1863512A (ru) |
| AP (1) | AP1826A (ru) |
| AT (1) | ATE358470T1 (ru) |
| BR (1) | BRPI0415322A (ru) |
| DE (1) | DE602004005734T2 (ru) |
| EA (1) | EA008944B1 (ru) |
| ES (1) | ES2286716T3 (ru) |
| MX (1) | MXPA06003479A (ru) |
| UA (1) | UA82564C2 (ru) |
| WO (1) | WO2005048978A2 (ru) |
| ZA (1) | ZA200603421B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110104267A1 (en) * | 2005-04-25 | 2011-05-05 | Aurobindo Pharma Limited | Pharmaceutical compositions of antiretrovirals |
| ES2574836T3 (es) | 2007-06-08 | 2016-06-22 | Boehringer Ingelheim International Gmbh | Formulación de liberación prolongada de nevirapina |
| WO2011008800A1 (en) * | 2009-07-14 | 2011-01-20 | Hill's Pet Nutrition, Inc. | Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
| CN102247332B (zh) * | 2011-01-27 | 2015-03-25 | 济南久创化学有限责任公司 | 一种拉米夫定片及其制备方法 |
| CN102225069B (zh) * | 2011-04-29 | 2013-05-08 | 陶珍珠 | 一种耐药性显著降低的药物组合物及其制备方法和其应用 |
| EP2714045A1 (en) * | 2011-05-30 | 2014-04-09 | Cipla Limited | Pharmaceutical antiretroviral composition |
| WO2013111147A1 (en) * | 2011-12-19 | 2013-08-01 | Hetero Research Foundation | Extended release compositions of nevirapine |
| CN107334743B (zh) * | 2016-07-15 | 2020-04-21 | 安徽贝克生物制药有限公司 | 一种齐多夫定、拉米夫定、奈韦拉平复方片及其制备方法 |
| CN114392239B (zh) * | 2022-01-10 | 2023-06-27 | 安徽贝克生物制药有限公司 | 一种拉米夫定、齐多夫定和依非韦伦的复方片及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL108838C (ru) * | 1956-03-27 | |||
| GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| US6177435B1 (en) * | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
| GB9821000D0 (en) * | 1998-09-28 | 1998-11-18 | Glaxo Group Ltd | Antiviral combinations |
| ZA200110500B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
-
2004
- 2004-09-29 DE DE602004005734T patent/DE602004005734T2/de active Active
- 2004-09-29 BR BRPI0415322-7A patent/BRPI0415322A/pt not_active IP Right Cessation
- 2004-09-29 EA EA200600679A patent/EA008944B1/ru not_active IP Right Cessation
- 2004-09-29 EP EP04817650A patent/EP1673072B1/en active Active
- 2004-09-29 ES ES04817650T patent/ES2286716T3/es active Active
- 2004-09-29 WO PCT/IN2004/000306 patent/WO2005048978A2/en active IP Right Grant
- 2004-09-29 AT AT04817650T patent/ATE358470T1/de not_active IP Right Cessation
- 2004-09-29 AP AP2006003597A patent/AP1826A/xx active
- 2004-09-29 MX MXPA06003479A patent/MXPA06003479A/es active IP Right Grant
- 2004-09-29 CN CNA2004800288530A patent/CN1863512A/zh active Pending
- 2004-09-29 US US10/574,320 patent/US20070231385A1/en not_active Abandoned
- 2004-09-29 UA UAA200604821A patent/UA82564C2/ru unknown
-
2006
- 2006-04-28 ZA ZA200603421A patent/ZA200603421B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200603421B (en) | 2007-09-26 |
| US20070231385A1 (en) | 2007-10-04 |
| WO2005048978A2 (en) | 2005-06-02 |
| BRPI0415322A (pt) | 2006-12-05 |
| EP1673072A2 (en) | 2006-06-28 |
| AP2006003597A0 (en) | 2006-04-30 |
| EA008944B1 (ru) | 2007-10-26 |
| EA200600679A1 (ru) | 2006-08-25 |
| AP1826A (en) | 2008-02-08 |
| WO2005048978A3 (en) | 2006-02-23 |
| ES2286716T3 (es) | 2007-12-01 |
| ATE358470T1 (de) | 2007-04-15 |
| CN1863512A (zh) | 2006-11-15 |
| DE602004005734T2 (de) | 2007-12-27 |
| DE602004005734D1 (de) | 2007-05-16 |
| EP1673072B1 (en) | 2007-04-04 |
| MXPA06003479A (es) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100728846B1 (ko) | 약물 함유량이 높은 정제 | |
| US8916195B2 (en) | Sustained release formulation of naltrexone | |
| KR20020075801A (ko) | 울혈성 심부전 치료의 부분적 지방산 산화 방지제 | |
| KR20100069685A (ko) | 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물 | |
| RU2664422C2 (ru) | Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения | |
| AU2014299447B2 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| ZA200603421B (en) | A controlled release pharmaceutical composition and a process for preparing the same | |
| PL179080B1 (pl) | Tabletka przeciwmigrenowa i sposób wytwarzania tabletki przeciwmigrenowej PL PL PL PL | |
| CA2835272A1 (en) | Pharmaceutical antiretroviral composition | |
| US20080145422A1 (en) | Galantamine tablet formulation | |
| US20160243034A1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| RU2336076C2 (ru) | Пероральное лекарственное средство для восполнения дефицита магния в организме | |
| WO2017029226A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| CN111655263A (zh) | 稳定的含硫胺素的药物制剂 | |
| US20210290548A1 (en) | Formulations of raltegravir | |
| KR101362679B1 (ko) | 프랄나카산의 지연 방출 제형 | |
| US20030004130A1 (en) | Homogeneous pharmaceutical compositions containing zidovudine and lamivudine | |
| KR20180101307A (ko) | 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 | |
| SK50222004A3 (sk) | Kompozície matrice s modifikovaným uvoľňovaním, s dlhodobým účinkom | |
| CN112569356B (zh) | 一种含有利尿剂的药物组合物 | |
| EP1275384A1 (en) | Pharmaceutical compositions for oral use, containing, in combination, metformin and glyclazide | |
| US20240041882A1 (en) | Mini-tablet dosage form of a viral terminase inhibitor and uses thereof | |
| WO2022228735A1 (en) | Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof | |
| US20120201883A1 (en) | Antiviral compositons |